Matrix metalloproteinase inhibitors.
The Division of Medicinal Chemistry offered a number of sub-sessions including this one on matrix metalloproteinase (MMP) inhibitors. The overexpression of matrix metalloproteinases has been associated with cancer malignancy, arthritis and several immune system-related infectious diseases such as sepsis. Encouraged by the impressive clinical trials of batimastat and marimastat (Figure 1; British Biotech plc), interest in MMP inhibitors has grown.